Reviva Pharmaceuticals Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.45.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.55.
During the past 3 years, the average EBIT per Share Growth Rate was 42.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 11.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Reviva Pharmaceuticals Holdings's EBIT per Share or its related term are showing as below:
RVPH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -120.1 Med: -18.95 Max: 42.3
Current: 42.3
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Reviva Pharmaceuticals Holdings was 42.30% per year. The lowest was -120.10% per year. And the median was -18.95% per year.
RVPH's 3-Year EBIT Growth Rate is ranked better than 80.65% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs RVPH: 42.30
Reviva Pharmaceuticals Holdings (OTCPK:RVPH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Reviva Pharmaceuticals Holdings EBIT per Share Related Terms
Reviva Pharmaceuticals Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reviva Pharmaceuticals Holdings EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reviva Pharmaceuticals Holdings (RVPH) has a EBIT per Share of $-4.55 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Reviva Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #227 out of 1173 companies in the Biotechnology industry, placing it in the top 19.4%.
Is Reviva Pharmaceuticals Holdings' EBIT per Share too high?
Reviva Pharmaceuticals Holdings' current EBIT per Share is $-4.55. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #227 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' EBIT per Share compare to AIM and BOLT?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #227 out of 1173 companies for EBIT per Share. This places Reviva Pharmaceuticals Holdings in the top 19% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Reviva Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Reviva Pharmaceuticals Holdings's current EBIT per Share is $-4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current EBIT per Share of $-4.55. The current EBIT per Share is $-4.55. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current EBIT per Share is $-4.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reviva Pharmaceuticals Holdings Business Description
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score
Get the complete analysis for RVPH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVPH has been successfully added to your 
